ESMO 2022 Conference Coverage
Playback speed
10 seconds
ESMO 2022: Early Decreases in KRAS Mutant Allele Frequency Predicts Clinical Benefit to the PLK1 Inhibitor Onvansertib in Combination With FOLFIRI/Bev in 2L Treatment of mCRC
By
ESMO 2022 Conference Coverage
FEATURING
Heinz-Josef Lenz
By
ESMO 2022 Conference Coverage
FEATURING
Heinz-Josef Lenz
58 views
September 27, 2022
Comments 0
Login to view comments.
Click here to Login
GI